Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Predictions

buy
Shop Apotheke Europe NV

Start price
Target price
Perf. (%)
€91.14
11.05.23
-
11.05.24
36.49%
11.05.24

buy
Fielmann AG

Start price
Target price
Perf. (%)
€46.58
11.05.23
-
11.05.24
2.62%
11.05.24

buy
Fielmann AG

Start price
Target price
Perf. (%)
€42.55
01.04.24
€44.00
01.04.25
5.52%
30.04.24

Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Higher EBIT margin than peer group
buy
Cancom SE

Start price
Target price
Perf. (%)
€27.94
01.04.24
€29.00
01.04.25
8.16%
14.04.24

Could be very worthwhile Investment >20% year
Revenue growth >5% per year expected
Higher EBIT margin than peer group
Fair valuation
buy
Grenke AG

Start price
Target price
Perf. (%)
€24.26
29.03.23
-
29.03.24
0.16%
30.03.24

buy
Shop Apotheke Europe NV

Start price
Target price
Perf. (%)
€144.95
10.02.24
€147.00
10.02.25
5.07%
29.03.24

Could be very worthwhile Investment >20% year
Revenue growth > 30% per year expected
EBIT growth > 30% per year expected
Very positive Cash Flow expected
buy
Metro AG ST

Start price
Target price
Perf. (%)
€7.46
17.03.23
-
17.03.24
-34.02%
18.03.24

Shop Apotheke Europe NV

Start price
Target price
Perf. (%)
€75.16
06.03.23
-
06.03.26
59.93%
11.03.24

Probably not worthwhile Investment
buy
Fielmann AG

Start price
Target price
Perf. (%)
€35.74
23.01.23
-
23.01.26
14.83%
11.03.24

Could be worthwhile Investment >10% per year
MorphoSys AG

Start price
Target price
Perf. (%)
€16.57
05.09.22
-
05.10.26
293.97%
11.03.24

Probably not worthwhile Investment
Ceconomy AG ST

Start price
Target price
Perf. (%)
€1.53
23.08.22
-
23.08.27
28.00%
11.03.24

Probably not worthwhile Investment
buy
AUTO1 Group SE

Start price
Target price
Perf. (%)
€29.96
04.10.21
-
04.10.24
-87.89%
11.03.24

Could be worthwhile Investment >10% per year
buy
Software AG

Start price
Target price
Perf. (%)
€19.44
13.02.23
-
13.02.24
98.05%
14.02.24

buy
Shop Apotheke Europe NV

Start price
Target price
Perf. (%)
€141.75
07.02.24
€144.00
07.02.25
2.26%
10.02.24

Could be very worthwhile Investment >20% year
Revenue growth > 30% per year expected
EBIT growth > 30% per year expected
Very positive Cash Flow expected
buy
CompuGroup Medical SE & Co. KGaA

Start price
Target price
Perf. (%)
€50.90
18.02.22
€56.00
08.04.24
-35.36%
07.02.24

EBIT growth >5% per year expected
ROE higher than 15% per year
positive Cash Flow expected
Could be worthwhile Investment >10% per year
buy
Shop Apotheke Europe NV

Start price
Target price
Perf. (%)
€140.35
06.02.24
€142.00
06.02.25
1.00%
07.02.24

Could be very worthwhile Investment >20% year
Revenue growth > 30% per year expected
EBIT growth > 30% per year expected
Very positive Cash Flow expected
buy
1&1 Drillisch AG

Start price
Target price
Perf. (%)
€18.98
16.01.24
-
16.01.25
-1.48%
31.01.24

buy
MorphoSys AG

Start price
Target price
Perf. (%)
€29.49
12.09.23
-
12.09.24
35.54%
31.01.24

buy
Shop Apotheke Europe NV

Start price
Target price
Perf. (%)
€105.85
25.07.23
-
25.07.24
23.57%
31.01.24

buy
Krones AG

Start price
Target price
Perf. (%)
€114.90
28.02.23
-
28.02.24
-0.70%
31.01.24

Shop Apotheke Europe NV

Start price
Target price
Perf. (%)
€64.90
27.01.23
-
27.01.24
103.93%
28.01.24

buy
Cancom SE

Start price
Target price
Perf. (%)
€32.90
24.01.23
€38.00
24.01.24
-10.76%
25.01.24

Could be worthwhile Investment >10% per year
buy
Südzucker AG

Start price
Target price
Perf. (%)
€14.26
10.01.24
€17.00
10.01.25
-8.49%
20.01.24

Higher EBIT margin than peer group
Revenue growth >5% per year expected
Future proof or reliable business model
Top 10 in its market
buy
Südzucker AG

Start price
Target price
Perf. (%)
€17.03
10.01.23
-
10.01.24
-16.15%
11.01.24

buy
Südzucker AG

Start price
Target price
Perf. (%)
€14.40
03.01.24
€19.00
03.01.25
-0.97%
06.01.24

Higher EBIT margin than peer group
Revenue growth >5% per year expected
Future proof or reliable business model
Top 10 in its market